JNCI Cancer Spectrum最新文献

{"title":"Leveraging geospatial data to support an implementation science approach to address lung cancer burden.","authors":"Tesla D DuBois, Alison C Brecher, Donna Edmondson, Evelyn Gonzalez, Charnita Zeigler-Johnson, Linda Fleisher, Shannon M Lynch","doi":"10.1093/jncics/pkaf047","DOIUrl":"10.1093/jncics/pkaf047","url":null,"abstract":"<p><p>The lung cancer mortality rate in Philadelphia is 16% higher than the national rate, making screening and prevention efforts paramount. To support prevention efforts, Fox Chase Cancer Center operates a comprehensive tobacco treatment program that employs an implementation science approach and provides more than 1000 individuals with various therapeutic strategies to support smoking cessation. Using the tobacco treatment program as a case study, this brief report describes the adaptation of the Reach, Effectiveness, Adoption, Implementation, and Maintenance framework into a geospatial format. Each dimension of the geospatial Reach, Effectiveness, Adoption, Implementation, and Maintenance framework results in a map that can help identify (1) target areas for intervention (Reach), (2) the degree to which the program is serving those areas (Effectiveness), (3) opportunities for partnership to support delivery (Adoption), (4) contextual factors influencing how the intervention is best delivered (Implementation), and (5) strategies for long-term integration of the intervention (Maintenance). This framework supports targeted, sustainable initiatives.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"General practitioner-led vs surgeon-led colon cancer survivorship care: a randomized clinical trial.","authors":"Julien A M Vos, Laura A M Duineveld, Thijs Wieldraaijer, Jan Wind, Wim B Busschers, Edanur Sert, Irma M Verdonck-de Leeuw, Henk C P M van Weert, Kristel M van Asselt","doi":"10.1093/jncics/pkaf052","DOIUrl":"10.1093/jncics/pkaf052","url":null,"abstract":"<p><p>The randomized controlled I CARE (Improving Care After colon canceR treatment in the Netherlands) trial evaluated the impact of general practitioner-led vs surgeon-led survivorship care on quality of life (QoL) in colorectal cancer survivors, alongside the effect of the eHealth application Oncokompas. The trial was conducted in 8 hospitals and 225 general practices across the Netherlands, including 303 patients who underwent surgery for stage I-III colon cancer or rectosigmoid carcinoma. Patients were randomly assigned into 4 groups: surgeon-led care, surgeon-led care with Oncokompas, general practitioner-led care, and general practitioner-led care with Oncokompas. QoL was assessed at multiple time points over 60 months. At 60 months, no clinically relevant differences in QoL were found between general practitioner-led and surgeon-led care (difference in summary score = -0.5, 95% CI = -1.6 to 0.5) or with Oncokompas (difference = 0.8, 95% CI = 0.0 to 1.6). In conclusion, neither general practitioner involvement nor access to Oncokompas led to clinically relevant improvements in long-term QoL. Survivorship care can be tailored to preferences. Netherlands Trial Register; NTR4860.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12163231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144191830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deriving risk-adapted starting ages of breast cancer screening according to polygenic risk score.","authors":"Xuechen Chen, Michael Hoffmeister, Hermann Brenner","doi":"10.1093/jncics/pkaf056","DOIUrl":"10.1093/jncics/pkaf056","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer screening starting at age 50 has been implemented in many countries. A recent recommendation of the US Preventive Services Task Force recommends lowering the starting age of breast cancer screening to 40. We aimed to assess the potential use of a polygenic risk score (PRS) for defining risk-adapted starting ages for women in the United States and various European countries as an alternative to population-wide lowering of the starting age.</p><p><strong>Methods: </strong>We determined 5-year cumulative risks of breast cancer for women at individual ages between 30 and 50 years in the United States and 4 large European countries (Germany, the UK, Italy, and France) based on the Surveillance, Epidemiology, and End Results program and GLOBOCAN 2022 database. Using relative risks for women within certain percentile ranges of a well-established PRS based on 313 risk variants (PRS313), we determined at which ages women with higher PRS313 would reach the breast cancer risk at age 50 of those at \"medium\" (40th to 60th percentile) risk.</p><p><strong>Results: </strong>Non-Hispanic White women in the United States in PRS313 percentile categories 60-80, 80-90, 90-95, 95-99, and >99 would reach the medium 5-year cumulative risk at age 50 already at ages 43, 41, 39, 37, and 34, respectively. Despite some variation in breast cancer incidence, risk-adapted starting ages of screening were similar across European countries.</p><p><strong>Conclusion: </strong>Consideration of a PRS would lead to risk-adapted starting ages of screening for breast cancer rather than a uniform advancement of starting age for White women in the United States and European countries.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12169415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of frequent monitoring of symptoms using the PRO-CTCAE in the NRG-BR004 clinical trial.","authors":"Hanna Bandos, Sungjin Kim, N Lynn Henry, Ron D Hays, Vinicius F Calsavara, Michael Luu, Gillian Gresham, Kit Y Lu, William J Irvin, J Marie Suga, Shahzad Siddique, Reena S Cecchini, André Rogatko, Greg Yothers, Mourad Tighiouart, Patricia A Ganz","doi":"10.1093/jncics/pkaf032","DOIUrl":"10.1093/jncics/pkaf032","url":null,"abstract":"<p><strong>Background: </strong>The PRO-CTCAE Measurement System was designed to enhance the quality of the standard toxicity evaluation in clinical trials. We developed a substudy within NRG-BR004, a phase III clinical trial in patients with newly documented HER2-positive metastatic breast cancer (MBC), to examine the added value and feasibility of frequent PRO-CTCAE data collection.</p><p><strong>Methods: </strong>Patients were asked to complete 23 PRO-CTCAE items assessing 12 symptoms. Electronic PRO (ePRO) reporting was preferred; however, paper administration was allowed. The data on items assessed before treatment initiation, then weekly during Cycles 1-2 (12 weeks), are presented herein. Feasibility of frequent assessment with ePRO reporting was assessed using these data and was predefined as ≥25% of patients being compliant (submitted ≥75% of scheduled assessments). We also examined PRO-CTCAE and clinician-reported CTCAE data for key symptoms using maximum toxicity grade and the toxicity index (TI).</p><p><strong>Results: </strong>Overall, 80% of patients (82 of 103) were compliant with expected weekly assessments (90% CI = 0.72 to 0.86). For all symptoms, the median maximum grade (TI value) of clinician-reported CTCAE was lower than the median maximum score (TI value) of patient-reported PRO-CTCAE. The differences in the data trend for weekly vs less frequent assessment were more apparent when data were evaluated using the TI vs the maximum score.</p><p><strong>Conclusions: </strong>Weekly assessments within the first two chemotherapy cycles were feasible in this trial of MBC patients. As expected, patients reported greater severity of symptoms than clinicians. Demonstrating the feasibility of frequent assessment could have implications for future research and clinical practice.</p><p><strong>Clinicaltrials.gov: </strong>NCT03199885 (https://clinicaltrials.gov/study/NCT03199885).</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12127797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer treatment outcomes and survival in Botswana by human immunodeficiency virus status: Ipabalele study results.","authors":"Surbhi Grover, Rohini Bhatia, Siqi Zhang, Salman Khan, Memory Bvochora-Nsingo, Sebathu Chiyapo, Dawn Balang, Lilie L Lin, Shalini Vinod, Mark N Polizzotto, Natalie Taylor, Karen Canfell, Nicola Zetola, Erle Robertson, Doreen Ramogola-Masire","doi":"10.1093/jncics/pkaf045","DOIUrl":"10.1093/jncics/pkaf045","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a leading morbidity/mortality cause, frequently co-occurring with human immunodeficiency virus (HIV) positivity, in Botswana. We examined long-term outcomes for Ipabalele study participants receiving curative chemoradiation for locally advanced cervical cancer (2015-2019) by HIV status.</p><p><strong>Methods: </strong>Clinical and outcome data were collected at baseline, treatment completion, and 3 months thereafter. Patients were followed for up to 5 years. Overall survival (OS) was evaluated using Kaplan-Meier curves and Cox regression.</p><p><strong>Results: </strong>The cohort comprised 295 patients (73.8% with HIV, younger at diagnosis [P < .001]) followed for a median of 44.2 months. Complete response was seen in 217/278 (76.1%) patients. Two- and 5-year OS rates were 73.4% and 59.9%, respectively, with no difference by HIV status. OS was associated negatively with advanced disease stage (III: hazard ratio [HR] 13.23, P < .001; IV: HR 7.8, P = .008) and positively with increased radiation (HR 0.977, P = .0005) and chemotherapy (HR 0.85, P = .005). Clinical response was associated negatively with advanced disease (IV: HR 0.113, P = .002) and positively with increased radiation (P = .009). Toxicity did not differ by HIV status. The most common grade-≥-2 non-hematological and hematological toxicities were radiation dermatitis (39.8%) and reduced white blood cell count (66.05%), respectively.</p><p><strong>Conclusions: </strong>In this cervical cancer cohort with good HIV status control, treatment outcomes and OS were associated with disease and treatment factors, not the HIV status. Early screening and education regarding treatment protocols are crucial to improve cervical cancer outcomes in Botswana.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12167595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of skilled nursing facility discharge on inpatient oncology quality outcomes.","authors":"Bonnie E Gould Rothberg, Jensa C Morris","doi":"10.1093/jncics/pkaf055","DOIUrl":"10.1093/jncics/pkaf055","url":null,"abstract":"<p><strong>Background: </strong>Hospitalist comanagement of inpatient oncology patients can improve length of stay (LOS), discharge time, and readmission rates. Identifying additional clinical factors affecting LOS and readmissions will guide further oncology hospitalist practice improvement.</p><p><strong>Methods: </strong>Hospitalizations on the Smilow Cancer Hospital medical oncology service with discharge to home under self-care (n = 622), home with services (n = 462), or skilled nursing facility (n = 152) from July 1, 2021, to July 31, 2022, were included. Outcomes included LOS, time of discharge, and 30-day readmission rate. Multivariable mixed linear (LOS, time of discharge) or Poisson (30-day readmission rates) models were adjusted for demographics, cancer type, severity of illness index, house staff team, and fiscal quarter and included a random intercept for patient. Analyses were 2-sided with a priori statistical significance of less than 0.05.</p><p><strong>Results: </strong>Patients discharged to a skilled nursing facility had a longer LOS (mean = 8.25 days, 95% confidence interval [CI] = 7.13 to 9.55 days) compared with patients discharged to home under self-care (mean = 3.04 days, 95% CI = 2.76 to 3.36 days) or with services (mean = 4.48 days, 95% CI = 4.03 to 4.97 days; P < .0001). Thirty-day readmission rates for patients discharged to a skilled nursing facility (43.99%) were 10 percentage points higher than those discharged home either under self-care (32.86%) or with services (33.48%; P = .14). These differences persisted in patients regardless of severity of illness index. Of the 152 patients discharged to a skilled nursing facility, 31 (20.3%) were readmitted specifically back to the medical oncology service within 60 days with 16 (51.6%) cycling back to a skilled nursing facility, which resulted in 11 second readmissions.</p><p><strong>Conclusion: </strong>For oncology patients requiring discharge to a skilled nursing facility, mindful and upfront discharge planning may improve care quality and efficiency.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing social and behavioral determinants of health data collection: insights from a pragmatic trial.","authors":"Kriyana P Reddy, Saania Mirpuri, Cara L Berkowitz, Elizabeth M de Jesus, Sarah B Hulse, Julia T Lewandowski, Kerry Q Coughlin, Merium L Burwell, Robin Evans, Jennifer Galetta, Sharon Rivera Sanchez, Trudy L Buckingham, Victoria Livingstone, Anne Marie McCarthy, Peter E Gabriel, Christine E Edmonds, Tamara J Cadet, Oluwadamilola M Fayanju","doi":"10.1093/jncics/pkaf040","DOIUrl":"10.1093/jncics/pkaf040","url":null,"abstract":"<p><p>In response to growing evidence and recognition that social and behavioral determinants of health (SBDOH) differentially affect the health-care experiences and outcomes of patients with cancer, there has been an increased focus on optimizing the routine collection of such data. In spring 2024, we launched a pragmatic clinical trial titled \"Effect of Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer\" (ClinicalTrials.gov identifier NCT06019988) at our academic health system. Instruments and modalities were selected following a process of collaborative and iterative consensus building that included an in-person discovery workshop with patients, national experts in psychometrics and SBDOH collection, health system leadership, faculty and staff stakeholders, and study sponsors. The final protocol, which used the Consolidated Framework for Implementation Research, follows a stepped-wedge cluster-randomized format and compares 3 SBDOH screening instruments-Accountable Health Communities Health-Related Social Needs Screening Tool, Health Leads Social Screening Tool, and the National Comprehensive Care Network Distress Thermometer and Problem List-and 3 delivery modalities-the Epic electronic health record patient portal; bidirectional text-based conversational agent (\"chatbot\"), and interactive voice response administered by phone. Despite substantial resources, multidisciplinary collaboration, and advanced planning, we encountered challenges related to patient navigation, stakeholder engagement, and technological integration. We describe our experience as a guide for others aspiring to realize real-world implementation of routine SBDOH data collection.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Building research infrastructure to advance precision medicine in colorectal cancer.","authors":"Stephanie L Schmit, Nicole C Loroña, Daniel Sobieski, Marco Matejcic, Nathalie T Nguyen, Hannah J Hoehn, Diana B Diaz, Kritika Shankar, Eric M Cockman, Esther Jean-Baptiste, Ya-Yu Tsai, R Blake Buchalter, Karina Brito, Rusche Wilson, Domenico Coppola, Clifton Fulmer, Ozlen Saglam, Alexandra F Tassielli, Francisca Beato, Ruifan Dai, Jennifer A Freedman, Kristen Purrington, Bo Hu, Daniel Mcgrail, Heather Gibson, Kun Jiang, Teresita Muñoz-Antonia, Idhaliz Flores, Edna Gordian, José A Oliveras Torres, Iona Cheng, Erin L Van Blarigan, Seth I Felder, Julian A Sanchez, Jason B Fleming, Erin M Siegel, Douglas Cress, Patricia Thompson, Mariana C Stern, Jamie K Teer, Jane C Figueiredo","doi":"10.1093/jncics/pkaf027","DOIUrl":"10.1093/jncics/pkaf027","url":null,"abstract":"<p><strong>Background: </strong>Addressing critical gaps in precision medicine initiatives in colorectal cancer (CRC) requires building larger collaborative studies.</p><p><strong>Methods: </strong>The Latino Colorectal Cancer Consortium (LC3) is a resource that harmonizes data collected in observational studies with data from individuals who identify as Hispanic/Latino with a diagnosis of primary colorectal adenocarcinoma. Data collected includes demographics, medical history, family history, and lifestyle risk factors from patient-completed surveys. Vital status, cause of death, treatment, and clinicopathological characteristics were obtained through medical chart abstraction, pathology reports, and/or linkage to state cancer registries. Blood, saliva, or normal colonic tissues were used to extract and genotype germline DNA. Tumor tissue (snap frozen or formalin-fixed paraffin-embedded) was evaluated by pathologists for diagnosis, tissue content, tumor cellularity, necrosis, immune infiltration, and additional histopathological characteristics. A centralized database with a virtual tumor repository was created to facilitate collaborative research.</p><p><strong>Results: </strong>As of April 2024, LC3 assembled data from 2210 patients (diagnosed 1994 to 2023). The mean age at diagnosis was 57 (range: 19-93) years; 54.3% of participants were male, and 62.0% had been diagnosed with colon cancer. Surveys were completed by 1722 (77.8%) participants. Ongoing multi-omics profiling on up to 600 patients include: genome-wide germline genotyping, paired tumor/normal whole exome sequencing, bulk RNA-seq, T cell receptor immunosequencing, and multiplex immunofluorescence.</p><p><strong>Conclusions: </strong>This consortium fills an important gap in research infrastructure in CRC as well as improving precision medicine initiatives for all individuals.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia.","authors":"Julie A Wolfson, Allison C Grimes, Michelle M Nuño, Subhash Ramakrishnan, David S Dickens, Michael E Roth, Wendy Woods, Kandice S Adams, Tawa Alabi, Melissa Beauchemin, Jennifer M Levine, Michele Scialla, Koh B Boayue, Charlotte L Kerber, Olivia Ponce, Sarah Vargas, George J Chang, Wendy Stock, Dawn Hershman, Emily Curran, Anjali Advani, Kristen O'Dwyer, Selina Luger, Jane Jijun Liu, David R Freyer, Lillian Sung, Susan K Parsons","doi":"10.1093/jncics/pkaf033","DOIUrl":"10.1093/jncics/pkaf033","url":null,"abstract":"<p><strong>Background: </strong>Individuals diagnosed with acute lymphoblastic leukemia (ALL) between adolescents and young adults aged 15-39 years face poor survival and unique challenges. We evaluated facility-level factors and guideline-concordant care among adolescents and young adults with ALL at National Cancer Institute Community Oncology Research Program (NCORP) practices.</p><p><strong>Methods: </strong>We assembled a retrospective cohort of adolescents and young adults aged 15-39 years with ALL treated at participating NCORPs between 2012 and 2016. NCORPs abstracted patient data and completed facility-level questionnaires for each clinical facility (study-defined criteria). The central review committee adjudicated whether treatment was concordant with adolescent and young adult-specific National Comprehensive Cancer Network ALL guidelines (ie, pediatric-inspired therapy or clinical trial). Guideline-concordant care was described by age, facility model (adult/internal medicine, pediatric, mixed [pediatric services within a general hospital]), and average annual adolescents and young adult ALL volume. Generalized linear mixed effects models estimated the odds of guideline-concordant care.</p><p><strong>Results: </strong>Adolescents and young adults receiving guideline-concordant care were younger (n = 196; median = 19.5 years) than those who did not (n = 31; median = 32.1 years). Guideline-concordant care was observed in many adolescents and young adults aged 22-39 years (68.8%), and nearly universal in those aged 15-21 years. In multivariable analyses, adolescents and young adults at adult/internal medicine clinical facilities had lower odds of guideline-concordant care (odds ratio = 0.02, 95% confidence interval = 0.0 to 0.18); there was no statistically significant association between annual adolescent and young ALL volume and receiving guideline-concordant care. Guideline-concordant care was observed more often in adult/internal medicine and/or mixed clinical facilities with communication between adult or pediatric counterparts, adolescents and young adult ALL clinical pathways, and/or adolescent and young adult-specific meetings.</p><p><strong>Conclusion: </strong>Guideline-concordant care among adolescents and young adults with ALL (specifically pediatric-inspired therapy) at NCORPs is associated with facility model (adult/internal medicine) but not adolescent and young adult ALL volume. Strategies to improve guideline-concordant care could include facilitating communication and clinical pathways at adult/internal medicine clinical facilities treating adolescent and young adult ALL.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy-induced peripheral neuropathy research: a National Institutes of Health (NIH) grant portfolio analysis (2014-2023).","authors":"Rachel D Altshuler, Lori M Minasian, Catherine A Schweppe, Nina S Kadan-Lottick","doi":"10.1093/jncics/pkaf039","DOIUrl":"10.1093/jncics/pkaf039","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating acute and long-term toxicity in cancer patients. We sought to describe the landscape of CIPN research funded by the National Institutes of Health (NIH) and identify gaps and opportunities.</p><p><strong>Methods: </strong>Using the NIH Query View Report system, we identified 180 competitive grants between 2014-2023 containing text pertaining to CIPN in the Abstract or Specific Aims. These were categorized as preclinical, clinical, or both and described by preclinical model, clinical population, CIPN assessments, and/or clinical trial design. We identified 5 additional NCI-funded trials through the NCORP network pertaining to CIPN.</p><p><strong>Results: </strong>Of 185 studies, 125 were preclinical, 56 clinical, and 4 both preclinical/clinical. Among preclinical studies, most studies used rodent CIPN models, of which 17% were tumor-bearing. Most preclinical studies investigated paclitaxel; none studied newer immune therapies. The 60 clinical studies were 53% observational and 47% interventional, focusing most frequently on breast cancer, unspecified cancers, and colorectal cancer diagnoses. Overall, 8% included patients <18 years, whereas a higher proportion included those 18-39 (85%), 40-64 (90%), and ≥65 (92%). Among 28 interventional trials, studies investigated behavioral interventions (39%), pharmacological agents (32%), and devices (29%).</p><p><strong>Conclusions: </strong>The number of CIPN grants awarded by NIH since 2014 represents a substantial investment, but critical gaps and opportunities remain. Preclinically, novel strategies to mimic human CIPN may improve translatability. Important gaps in CIPN-associated cancer diagnoses and therapy exposures, including novel agents, would benefit from future research. Also, clinical studies are needed in young patients with potential long-term CIPN.</p>","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}